Core Viewpoint - The company has successfully integrated AI technology into the protein modification process, creating a closed-loop iterative optimization workflow that combines AI computation and simulation with high-throughput wet experiments [1] Group 1: AI Technology Application - The company utilizes AI calculations and simulations in the protein modification process [1] - A combination of "dry experiments" and high-throughput "wet experiments" is employed to enhance the research and development process [1] - The introduction of force-field-based computer virtual screening methods contributes to the optimization workflow [1] Group 2: Product Development - The company has successfully developed specific proteins through its innovative approach [1]

Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively expanding its product offerings in the CAR-T cell therapy and recombinant protein sectors, benefiting from the depreciation of the RMB and recognition as a "specialized and innovative" enterprise [2][3][4]. Group 1: Company Developments - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product range related to cell and gene therapy [2]. - The company has developed high-quality recombinant proteins through its proprietary biotechnology platform, addressing various disease targets and biomarkers [2]. - The company is developing products related to monkeypox virus, including recombinant proteins and test kits, to support vaccine and therapeutic drug development [2]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit of 132 million yuan, up 58.61% year-on-year [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Market Position and Recognition - The company has been recognized as a "national-level specialized and innovative small giant enterprise," indicating its strong market position, innovation capabilities, and high market share [3]. - The company operates in the pharmaceutical and biotechnology sector, focusing on recombinant proteins and other biological products, with a significant portion of its revenue derived from these areas [8][9].

Core Viewpoint - The company has announced the approval of several key proposals at its first extraordinary general meeting of shareholders in 2026, including plans for issuing H shares and listing on the Hong Kong Stock Exchange [1] Group 1 - The company will issue H shares and list on the Hong Kong Stock Exchange [1] - The company is transitioning to an overseas fundraising joint-stock company [1] - The company has outlined a plan for the use of funds raised from the issuance of H shares [1]

证券代码：301080 证券简称：百普赛斯 公告编号：2026-001 北京百普赛斯生物科技股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2026 年 1 月 6 日（星期二）下午 14:00 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的时间为 2026 年 1 月 6 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2026 年 1 月 6 日 9:15-15:00 期间的任意时间。 3、会议召开地点：北京市北京经济技术开发区宏达北路 8 号北京百普赛斯 生物科技股份有限公司（以下简称"公司"）二层会议室 4、会议的召开方式：现场表决与网络投票相结合的方式 5、会议召集人：公司董事会 6、会议主持人：经过半数董事推选，本次会议由董事苗景赟先生主持。 7、本次股东会的召集 ...

上海市通力律师事务所 关于北京百普赛斯生物科技股份有限公司 2026 年第一次临时股东会的法律意见书 致:北京百普赛斯生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受北京百普赛斯生物科技股份有限公司 (以下简称"公司")的委托,指派本所黄雅程律师、张幸律师(以下简称"本所律师")根据 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规 和规范性文件(以下统称"法律法规")及《北京百普赛斯生物科技股份有限公司章程》(以 下简称"公司章程")的规定就公司 2026 年第一次临时股东会(以下简称"本次股东会") 相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中,公司己向本所保证,公司提供予本所之文件中的所有签 署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有效 的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东会召集和召开的程序、出席本次股东会人员资格 和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 ...

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing growth in its business segments, particularly in cell immunotherapy and recombinant proteins, while benefiting from the depreciation of the RMB and being recognized as a "specialized and innovative" enterprise [2][3][4]. Group 1: Business Performance - The company reported a revenue of 613 million yuan for the period from January to September 2025, representing a year-on-year growth of 32.26% [9]. - The net profit attributable to the parent company for the same period was 132 million yuan, showing a year-on-year increase of 58.61% [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Product Development - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - It has developed a range of high-quality recombinant proteins targeting various diseases and biomarkers, supporting the research and production of biopharmaceuticals [2]. - The company is actively developing products related to monkeypox virus, including recombinant proteins, antibodies, and test kits, to aid in vaccine and therapeutic drug development [2]. Group 3: Market Position and Recognition - The company has been recognized as a "national-level specialized and innovative small giant enterprise," which signifies its strong market position and innovation capabilities [3]. - It operates in the pharmaceutical and biotechnology sector, focusing on recombinant proteins and related technologies [8]. - The company has a diverse product revenue structure, with 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, and 3.04% from technical services [8].

Group 1 - The core viewpoint of the news is the performance and financial status of Beijing Baipusi Biotechnology Co., Ltd., which saw a stock price increase of 5.07% to 56.74 CNY per share, with a total market capitalization of 9.486 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - From the perspective of fund holdings, Guotai Fund has a significant position in Baipusi, with the Guotai Innovation Medical Mixed Fund A (018159) holding 21,600 shares, representing 5.2% of the fund's net value, making it the seventh-largest holding [2] - The Guotai Innovation Medical Mixed Fund A was established on April 18, 2023, with a latest scale of 17.7778 million CNY, and has achieved a year-to-date return of 38.09%, ranking 2210 out of 8155 in its category [2] Group 3 - The fund manager of Guotai Innovation Medical Mixed Fund A is Qiu Xiaoxu, who has been in the position for 3 years and 144 days, managing assets totaling 676 million CNY, with the best fund return during the tenure being 5.58% and the worst being 0.5% [3]

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.02% on December 26, with Jindike leading the drop, while the Shanghai Composite Index rose by 0.1% and the Shenzhen Component Index increased by 0.54% [1] Group 1: Market Performance - The closing prices and performance of key biopharmaceutical stocks showed mixed results, with Heyi Biotech rising by 3.17% to 71.61 and Jindike falling by 2.54% to 21.88 [1][2] - The trading volume for Heyi Biotech was 33,900 shares, with a transaction value of 239 million yuan, while Jindike had a trading volume of 38,900 shares and a transaction value of 85.44 million yuan [1][2] Group 2: Capital Flow - The biopharmaceutical sector saw a net outflow of 185 million yuan from institutional investors, while retail investors had a net inflow of 142 million yuan [2] - Key stocks like Gann Li Pharmaceutical had a net inflow of 13.59 million yuan from institutional investors, but a net outflow of 24.81 million yuan from retail investors [3]